Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


First published on August 19, 2008
This version was published on January 1, 2009
Neuro Oncol 2009 11(1):59-68; DOI:10.1215/15228517-2008-063
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
11/1/59    most recent
15228517-2008-063v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, R.
Right arrow Articles by Chang, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Duke University Press

Special Focus: Glioma

Quality of life in low-grade glioma patients receiving temozolomide

Raymond Liu, Karla Solheim, Mei-Yin Polley, Kathleen R. Lamborn, Margaretta Page, Anne Fedoroff, Jane Rabbitt, Nicholas Butowski, Michael Prados and Susan M. Chang

Department of Medicine, Division of Hematology, Oncology (R.L.), Medical School (K.S.), Department of Neurological Surgery, Neuro-Oncology (M.-Y.P., K.R.L., M.P., A.F., J.R., N.B., M.P., S.M.C.), University of California, San Francisco, San Francisco, CA, USA

Address correspondence to Raymond Liu, Clinical Fellow, Hematology/Oncology/Neuro-Oncology, University of California, San Francisco, 400 Parnassus Ave., Room A-808, San Francisco, CA 94143-2167, USA (Raymond.Liu{at}ucsf.edu).

The purpose of this study was to describe the quality of life (QOL) of low-grade glioma (LGG) patients at baseline prior to chemotherapy and through 12 cycles of temozolomide (TMZ) chemotherapy. Patients with histologically confirmed LGG with only prior surgery were given TMZ for 12 cycles. QOL assessments by the Functional Assessment of Cancer Therapy–Brain (FACT-Br) were obtained at baseline prior to chemotherapy and at 2-month intervals while receiving TMZ. Patients with LGG at baseline prior to chemotherapy had higher reported social well-being scores (mean difference = 5.0; p < 0.01) but had lower reported emotional well-being scores (mean difference = 2.2; p < 0.01) compared to a normal population. Compared to patients with left hemisphere tumors, patients with right hemisphere tumors reported higher physical well-being scores (p = 0.01): 44% could not drive, 26% did not feel independent, and 26% were afraid of having a seizure. Difficulty with work was noted in 24%. Mean change scores at each chemotherapy cycle compared to baseline for all QOL subscales showed either no significant change or were significantly positive (p < 0.01). Patients with LGG on TMZ at baseline prior to chemotherapy reported QOL comparable to a normal population with the exception of social and emotional well-being, and those with right hemisphere tumors reported higher physical well-being scores compared to those with left hemisphere tumors. While remaining on therapy, LGG patients were able to maintain their QOL in all realms. LGG patients' QOL may be further improved by addressing their emotional well-being and their loss of independence in terms of driving or working.

Key Words: brain tumor • chemotherapy • low-grade glioma • quality of life • temozolomide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Copyright 2009 by Society for Neuro-Oncology